Compare BIDU & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIDU | KRMD |
|---|---|---|
| Founded | 2000 | 1980 |
| Country | China | United States |
| Employees | 33500 | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3B | 195.7M |
| IPO Year | N/A | 2019 |
| Metric | BIDU | KRMD |
|---|---|---|
| Price | $110.52 | $4.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $154.38 | $6.50 |
| AVG Volume (30 Days) | ★ 1.7M | 129.7K |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,127,366.00 |
| Revenue This Year | $5.56 | $20.32 |
| Revenue Next Year | $7.54 | $17.38 |
| P/E Ratio | $42.45 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $74.71 | $1.87 |
| 52 Week High | $165.30 | $6.61 |
| Indicator | BIDU | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.14 | 42.44 |
| Support Level | $108.01 | $4.31 |
| Resistance Level | $130.75 | $4.34 |
| Average True Range (ATR) | 3.16 | 0.18 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 24.79 | 57.89 |
Most of Baidu's revenue comes from Baidu core, with the rest coming from video-streaming subsidiary iQiyi. The firm's main businesses include online marketing services from its search engine, AI cloud infrastructure, AI applications, AI marketing, and autonomous driving.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.